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Outcomes of antiretroviral therapy among younger versus older 
adolescents and adults in an urban clinic, Zimbabwe
C. M. J. Matyanga,1 K. C. Takarinda,2,3 P. Owiti,4 T. Mutasa-Apollo,2 O. Mugurungi,2 L. Buruwe,1 A. J. Reid5
Human immunodeficiency virus infection and the acquired immune-deficiency syndrome (HIV/
AIDS) remain a significant public health burden in Af-
rica, and Zimbabwe has not been spared. Zimbabwe is 
among 15 countries that account for nearly 75% of 
people living with HIV/AIDS globally; current HIV 
prevalence in Zimbabwe is 17% (2014 estimate).1,2 
From the advent of antiretroviral therapy (ART), Zim-
babwe scaled up treatment from 8000 patients in 2004 
to 788 000 by 2014.2,3 As the cohort of ART patients 
has increased, retaining patients in care has become a 
challenge. Retention is vital for viral suppression, 
which leads to better survival and lower HIV 
transmission.4,5
Retention of people living with HIV (PLHIV) in 
treatment has been well studied, with a systematic re-
view and meta-analysis of studies in sub-Saharan Af-
rica showing a reduction in mean retention rates over 
time.6 Most studies in the meta-analysis concerned 
adult patients, although some included paediatric 
patients.
The World Health Organization’s (WHO’s) defini-
tion for adolescents is age 10–19 years.7 Most studies 
on ART retention have reported on adults, with ado-
lescents included within the adult age group, making 
it difficult to extract information specific to 
adolescents.8–11
Emerging evidence suggests that adolescents are 
falling behind in HIV care compared to adults as a re-
sult of not receiving specialised attention and ser-
vices.12,13 A study performed in seven African coun-
tries, excluding Zimbabwe, showed that adolescents 
and young adults combined (age 15–24 years) had 
higher rates of loss to follow-up (LTFU) and higher 
mortality compared with older adults (age 50 
years).14 What is unknown is whether there are differ-
ences in attrition rates between younger vs. older ado-
lescents or between younger vs. older adults.
A systematic search for publications on ART out-
come studies in PubMed, Cochrane Database, Goo-
gle Scholar and ClinicalTrial.gov, comparing 
younger vs. older adolescents and younger vs. older 
adults, showed that with respect to ART retention, 
adolescents (age 10–19 years) were often misclassi-
fied as adults aged 15 years,8,9 16 years11 or 18 
years.10 No studies reported attrition rates within 
the adolescent age group or between younger and 
older adults.
The Epworth Polyclinic in Epworth, Zimbabwe, has 
good records on ART care for all age groups; this pre-
sented an opportunity to compare the retention and 
attrition rates in younger and older adolescents as well 
as in younger and older adults during a time period 
when adolescent services were the same as for adults 
in Zimbabwe.
The aim of this study was to describe and compare 
demographic and clinical characteristics and attrition 
from ART care between HIV-infected younger (age 10–
14 years) vs. older adolescents (age 15–19 years) and 
between younger (age 20–29 years) vs. older adults 
(age 30 years) started on ART between January 2010 
and December 2011 at Epworth Polyclinic in 
Zimbabwe.
METHODS
Design
This was a retrospective cohort study.
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Setting: A non-governmental organisation-supported 
clinic offering health services including antiretroviral ther-
apy (ART).
Objective: To compare ART retention between younger 
(age 10–14 years) vs. older (age 15–19 years) adolescents 
and younger (age 20–29 years) vs. older (age 30 years) 
adults and determine adolescent- and adult-specific attri-
tion-associated factors among those initiated on ART be-
tween 2010 and 2011.
Design: Retrospective cohort study.
Results: Of 110 (7%) adolescents and 1484 (93%) 
adults included in the study, no differences in retention 
were observed between younger vs. older adolescents at 
6, 12 and 24 months. More younger adolescents were 
initiated with body mass index 16 kg/m2 compared 
with older adolescents (64% vs. 47%; P = 0.04). There 
were more females (74% vs. 52%, P  0.001) and fewer 
patients initiating ART with CD4 count 350 cells/mm3 
(77% vs. 81%, P = 0.007) among younger vs. older 
adults. Younger adults demonstrated more attrition than 
older adults at all time-points. No attrition risk factors 
were observed among adolescents. Attrition-associated 
factors among adults included being younger, having a 
lower CD4 count and advanced human immunodefi-
ciency virus disease at initiation, and initiation on a stavu-
dine-based regimen.
Conclusion: Younger adults demonstrated greater attri-
tion and may require more attention. We were unable to 
demonstrate differences in attrition among younger vs. 
older adolescents. Loss to follow-up was the main reason 
for attrition across all age groups. Overall, earlier presen-
tation for ART care appears important for improved ART 
retention among adults.
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Setting
General setting
Zimbabwe, located in southern Africa, is a low-income 
country.15 The public health system is the largest pro-
vider of health care services, complemented by mis-
sion hospitals and non-governmental organisations 
(NGOs). Based on 2011 data, HIV/AIDS was among the 
top five causes of mortality for all age groups in 
Zimbabwe.16
Study site
Epworth is an informal high-density settlement lo-
cated 15 km outside Harare. Over 70% of the popula-
tion resides in plots that were not officially allocated.17 
Based on the 2012 census, Epworth represented 8% of 
the population of Harare.18 Health services in Epworth 
are provided by two clinics, the Epworth Polyclinic 
and Epworth Mission clinic.
The Epworth Polyclinic offers general health ser-
vices integrated with HIV and tuberculosis (TB) ser-
vices. Since 2006, Médecins Sans Frontières-Holland 
(MSF-H) has supported the clinic by providing inte-
grated basic health care services, including antenatal 
care (ANC), general primary health care, HIV and TB 
services and therapeutic feeding. The clinic was re-
cently handed over to the Ministry of Health. As of 
December 2014, 9290 patients had been registered in 
the ART programme.
Management of HIV/AIDS in Zimbabwe
Medical criteria for initiating ART in adults and 
adolescents
Between 2010 and 2011, ART was provided according 
to the 2010 national ART guidelines,19 adapted from 
the 2010 WHO guidelines: treatment was the same for 
both adolescents (age 10–19 years) and adults (age 20 
years).20 ART was offered to all eligible patients with a 
confirmed HIV diagnosis and a CD4 count of 350 
cells/mm3, and those with WHO clinical Stage III and 
IV, irrespective of CD4 count. ART was initiated regard-
less of CD4 count among patients with active TB dis-
ease and with hepatitis B virus (HBV) co-infection with 
severe chronic liver disease.19
Recommended treatment regimens for adults and 
adolescents
In 2010–2011, the preferred first-line ART regimen in-
cluded tenofovir (TFV), lamivudine (or emtricitabine) 
and nevirapine (NVP). The alternative regimen was zi-
dovudine (ZDV), lamivudine and NVP. Stavudine (d4T) 
was being phased out, but was still available for those 
who were already using it. Single-drug substitutions 
within the same drug class were recommended for 
drug toxicities and if TB was being concurrently 
treated, e.g., efavirenz was substituted for NVP.
Patient monitoring and follow-up
Following ART initiation, patients were seen every 2 
weeks for the first month, then monthly for the next 3 
months. If they were stable after the initial 3 months, 
they were seen every 3 months thereafter. While the 
government provided antiretroviral medicines free of 
charge, patients were expected to pay a minimal con-
sultation fee and laboratory-associated costs, such as 
CD4 tests, full blood count and radiography. Recom-
mended clinical monitoring indices included patient 
weight, WHO clinical stage, development of opportu-
nistic infections and CD4 count.19
Patient population
All HIV-infected adolescents (age 10–19 years) and 
adults (age 20 years) registered and initiated in the 
ART register at the Epworth clinic from January 2010 
to December 2011 were included in the study.
Data variables, data collection and sources of data
Variables collected included demographics, baseline 
clinical and immunological characteristics, date of last 
clinic attendance, date of last scheduled visit, initial 
and latest ART regimen and date of ART outcome. ART 
outcomes at date of last clinic attendance were defined 
as still in care, defaulted (absent from next scheduled 
clinic visit for 90 days), LTFU (absent for 90 days 
after next scheduled clinic/pharmacy appointment), 
died, stopped ART or transferred out. Thinness in ado-
lescents was graded as body mass index (BMI) 16 kg/
m2 (Grade 3), 16–16.9 kg/m2 (Grade 2) and 17–18.4 kg/
m2 (Grade 1).20
For this study, ‘retention’ referred to patients who 
were alive and receiving ART at Epworth Polyclinic, 
while ‘attrition’ referred to patients documented as 
having died, stopped ART, defaulted or LTFU. Trans-
ferred-out patients were excluded from calculations of 
attrition and retention, as we could not verify their 
status.
Sources of data were individual patient ART clinic 
booklets and registers from the Epworth Polyclinic. Im-
munological characteristics were based on laboratory 
test results. Baseline clinical characteristics and out-
comes were validated using individual patient charts. A 
data abstraction sheet was used to collect data from 
medical records between September and October 2015. 
Outcomes were assessed in October 2015. Each patient 
was followed up for a maximum of 24 months.
Analysis
EpiData was used for data entry and analysis (version 
3.1 for entry and version 2.2.2.182 for analysis, EpiData 
Association, Odense, Denmark) and Stata/IC 13.1 
(StataCorp, College Station, TX, USA) was used for mul-
tivariate analysis. Differences in baseline clinical char-
acteristics and outcomes were compared within the 
two adolescent and adult groups using proportions. As-
sociations were calculated using the χ² test for associa-
tions. Cox proportional hazards models were used to 
identify factors associated with attrition using univari-
ate and multivariate-adjusted hazard ratios and their 
respective 95% confidence intervals (CI). Variables ex-
cluded in the multivariate Cox proportional hazards 
models had a P value  0.25 in the univariate analysis 
(i.e., switching to second-line ART treatment). ‘TB at 
ART initiation’ was excluded because of collinearity 
with ‘WHO clinical staging at ART initiation’. Propor-
tional hazards assumptions were met by plotting simi-
lar shapes for graphs of the survival function vs. sur-
vival time. P values 0.05 were considered statistically 
significant.
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RESULTS
A total of 1594 HIV-infected patients were enrolled on ART at Ep-
worth Polyclinic, of whom 110 (7%) were adolescents and 1484 
(93%) were adults. A larger proportion of younger adolescents 
had Grade 3 BMI compared with older adolescents, while fewer 
had BMI of between 18.5 kg/m2 and 24.9 kg/m2. A higher propor-
tion of younger adolescents started on ZDV-based ART (Table 1).
More younger adults than older adults were females and had 
started ART at WHO Stage IV, although fewer had a CD4 count 
350 cells/mm3 (Table 2). In a sub-analysis of baseline CD4 count 
by sex, a higher proportion of older adult males vs. older adult fe-
males were initiated on ART with CD4 counts 350 cells/mm3; 
no differences were noted among younger adults.
There was no difference in retention or attrition at 6, 12 and 
24 months between younger and older adolescents, although 
overall retention declined over the three time periods in both 
groups (Table 3). Older adults tended to be in care longer, with 
greater retention (less attrition) at 6, 12 and 24 months compared 
to younger adults (Table 4).
Among adolescents, initiation on ART with WHO Stage IV 
(compared to Stage I) was associated with more attrition (Table 5). 
Factors associated with lower attrition among adults included be-
ing older, having a higher CD4 count at initiation and initiation 
on a TFV-based regimen. Having a high WHO clinical stage at 
baseline was associated with higher risk of attrition (Table 6).
Most patients who were not retained in care across all age 
groups were recorded as LTFU (Table 7).
TABLE 1 Comparison of demographic and baseline clinical characteristics 
between younger and older HIV-infected adolescents initiating ART between 2010 
and 2011 at Epworth Polyclinic, Epworth, Zimbabwe
Characteristic
Younger adolescents
(age 10–14 years)
n = 59
Older adolescents
(age 15–19 years)
n = 51
P valuen (%) n (%)
Sex
 Male 29 (49) 19 (37) 0.2
 Female 30 (51) 32 (63)
CD4 count, cells/mm3
 100 7 (12) 8 (16) 0.8
 100–200 11 (19) 6 (12)
 201–350 20 (34) 19 (37)
 351–500 8 (13) 5 (10)
 500 13 (22) 13 (25)
WHO clinical staging
 Stage I 26 (44) 17 (33) 0.6
 Stage II 11 (19) 14 (28)
 Stage III 18 (30) 15 (29)
 Stage IV 4 (7) 3 (6)
 Not recorded 0 2 (4)
BMI, kg/m2
 16 (Grade 1) 38 (64) 24 (47) 0.04
 16–16.9 (Grade 2) 16 (27) 7 (14) 0.09
 17–18.4 (Grade 3) 4 (7) 9 (17) 0.08
 18.5–24.9 1 (2) 11 (22) 0.001
TB at ART initiation 7 (12) 3 (6) 0.3
ART regimen at initiation
 Stavudine-based 42 (71) 41 (80) 0.3
 Zidovudine-based 13 (22) 3 (6) 0.02
 Tenofovir-based 4 (7) 7 (14) 0.2
HIV status disclosed
 Yes 44 (75) 37 (72) 0.9
 No 5 (8) 4 (8)
 Not recorded 10 (17) 10 (20)
HIV = human immunodeficiency virus; ART = antiretroviral therapy; WHO = World Health Organiza-
tion; BMI = body mass index; TB = tuberculosis.
Public Health Action ART outcomes in Zimbabwe  100
TABLE 2 Comparison of demographic and baseline clinical characteristics 
between younger and older HIV-infected adults initiating ART between 2010 and 
2011 at Epworth Polyclinic, Epworth, Zimbabwe
Characteristics
Younger adults
(age 20–29 years)
n = 237
Older adults
(age 30 years)
n = 1247
P valuen (%) n (%)
Sex
 Male 60 (25) 594 (48) 0.001
 Female 176 (74) 653 (52)
 Not recorded 1 (1) 0
CD4 count, cells/mm3
 100 35 (15) 264 (21) 0.02
 100–200 46 (20) 321 (25) 0.04
 201–350 100 (42) 435 (35) 0.03
 351–500 29 (12) 132 (11) 0.5
 >500 27 (11) 95 (8) 0.05
WHO clinical staging
 Stage I 96 (40) 472 (38) 0.5
 Stage II 39 (16) 286 (23) 0.03
 Stage III 89 (38) 445 (35) 0.6
 Stage IV 12 (5) 34 (3) 0.06
 Not recorded 1 (1) 10 (1)
BMI, kg/m2
 18.5 65 (27) 364 (29) 0.5
 18.5–24.9 148 (63) 744 (59)
 25–29.9 21 (9) 104 (8)
 30 3 (1) 34 (3)
 Not recorded 0 1 (1)
TB at ART initiation 30 (13) 142 (11) 0.6
ART regimen at initiation
 Stavudine-based 176 (74) 957 (77) 0.4
 Zidovudine-based 27 (12) 51 (4) 0.001
 Tenofovir-based 34 (14) 239 (19) 0.08
HIV = human immunodeficiency virus; ART = antiretroviral therapy; WHO = World Health Organiza-
tion; BMI = body mass index; TB = tuberculosis.
TABLE 3 ART outcomes at 6, 12 and 24 months among HIV-infected adolescents enrolled at 
Epworth Polyclinic, Epworth, Zimbabwe between 2010 and 2011
Younger adolescents
(age 10–14 years)
n = 51*
Older adolescents
(age 15–19 years)
n = 48*
P valuen % (95%CI) n % (95%C)
Median time in care, months [IQR] 49 [36–59] 52 [35–59] 0.7
6-month outcome
 Retention† 47 92 (82–97) 44 92 (80–97) 0.9
 Attrition‡ 4 8 (3–19) 4 8 (3–20)
12-month outcome
 Retention† 46 90 (79–96) 41 85 (73–93) 0.5
 Attrition‡ 5 10 (4–21) 7 15 (7–27)
24-month outcome
 Retention† 42 82 (70–90) 39 81 (68–90) 0.9
 Attrition‡ 9 18 (10–30) 9 19 (10–32)
* Transfers-out (younger adolescents, n = 8; older adolescents, n = 3) were not included in the analysis.
† Alive and still in care.
‡ Died, lost to follow-up, defaulted or stopped ART.
ART = antiretroviral therapy; HIV = human immunodeficiency virus; CI = confidence interval; IQR = interquartile range.
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TABLE 4 ART outcomes at 6, 12 and 24 months among HIV-infected adults enrolled at Epworth 
Polyclinic, Epworth, Zimbabwe between 2010 and 2011
Younger adults 
(age 20–29 years)
n = 208*
Older Adults 
(age 30 years)
n = 1159*
P valuen  % (95%CI)) n % (95%CI)
Median time in care, months [IQR] 45 [21–54] 50 [41–58] <0.001
6-month outcome
 Retention† 187 90 (85–93) 1112 96 (95–97) <0.001
 Attrition‡ 21 10 (7–15) 47 4 (3–5)
12-month outcome
 Retention† 175 84 (79–89) 1054 91 (89–93) 0.003
 Attrition‡ 33 84 (79–89) 105 9 (8–11)
24-month outcome
 Retention† 154 84 (79–89) 1000 86 (84–88) <0.001
 Attrition‡ 54 26 (21–32) 159 14 (12–16)
* Transfers-out (younger adults, n = 29; older adults, n = 88) were not included in the analysis.
† Alive and still in care.
‡ Died, lost to follow-up, defaulted or stopped ART.
ART = antiretroviral therapy; HIV = human immunodeficiency virus; CI = confidence interval; IQR = interquartile range.
TABLE 5 Factors associated with attrition among HIV-infected 
adolescents initiating ART between 2010 and 2011 at Epworth 
Polyclinic, Epworth, Zimbabwe 
Characteristic Crude HR (95%CI) Adjusted HR (95%CI)
Age group*
 Younger adolescents Reference Reference
 Older adolescents 1.16 (0.6–2.25) 0.68 (0.30–1.53)
Sex
 Male Reference Reference
 Female 1.15 (0.58–2.29) 1.31 (0.60–2.87)
CD4 count, cells/mm3
 <100 Reference Reference
 101–200 0.27 (0.07–1.00) 0.23 (0.05–1.00)
 201–350 0.42 (0.18–0.99) 0.45 (0.15–1.30)
 350–500 0.32 (0.09–1.19) 0.32 (0.08–1.33)
 >500 0.40 (0.15–1.04) 0.43 (0.12–1.55)
WHO clinical staging
 Stage I Reference Reference
 Stage II 1.14 (0.44–2.95) 1.42 (0.46–4.40)
 Stage III 1.50 (0.66–3.39) 1.86 (0.70–4.90)
 Stage IV 3.29 (0.92–11.86) 7.53 (1.64–34.62)
BMI, kg/m2
 <16.0 Reference Reference
 16.0–16.9 0.78 (0.31–1.97) 0.64 (0.22–1.90)
 17.0–18.4 2.03 (0.75–5.48) 2.43 (0.74–7.94)
 18.5–24.9 1.65 (0.65–4.16) 1.35 (0.40–4.57)
ART regimen at initiation
 Stavudine-based Reference Reference
 Zidovudine-based 0.42 (0.13–1.38) 0.17 (0.03–1.12)
 Tenofovir-based† — —
HIV disclosure status
 No Reference Reference
 Yes 0.71 (0.22–2.37) 1.05 (0.27–4.08)
 Not recorded† — —
* Younger adolescents (age 10–14 years); older adolescents (age 15–19 years).
† Numbers too few to produce HR at 95%CI.
HIV = human immunodeficiency virus; ART = antiretroviral therapy; HR = hazard ra-
tio; CI = confidence interval; WHO = World Health Organization; BMI = body mass 
index.
TABLE 6 Factors associated with attrition among HIV-infected 
adults initiating ART between 2010 and 2011 at Epworth Polyclinic, 
Epworth, Zimbabwe
Characteristic Crude HR (95%CI) Adjusted HR (95%CI)
Age group*
 Young adults Reference Reference
 Older adults 0.56 (0.45–0.7) 0.52 (0.41–0.66)
Sex 
 Male Reference Reference
 Female 0.9 (0.74–1.08) 0.92 (0.75–1.12)
CD4 count, cells/mm3
 <100 Reference Reference
 101–200 0.76 (0.59–0.97) 0.84 (0.65–1.09)
 201–350 0.53 (0.42–0.68) 0.61 (0.47–0.79)
 350–500 0.47 (0.32–0.68) 0.5 (0.34–0.73)
 >500 0.6 (0.41–0.88) 0.61 (0.41–0.91)
WHO clinical staging
 Stage I Reference Reference
 Stage II 1.19 (0.91–1.57) 1.23 (0.93–1.62)
 Stage III 1.72 (1.37–2.15) 1.58 (1.25–1.99)
 Stage IV 5.31 (3.59–7.87) 4.83 (3.22–7.24)
BMI, kg/m2
 <18.5 Reference Reference
 18.5–24.9 0.94 (0.76–1.15) 1.01 (0.82–1.25)
 25–29.9 0.69 (0.46–1.04) 0.8 (0.53–1.22)
 30 0.68 (0.33–1.38) 0.95 (0.46–1.96)
ART regimen at initiation
 Stavudine-based Reference Reference
 Zidovudine-based 0.93 (0.61–1.42) 1.02 (0.66–1.57)
 Tenofovir-based 0.57 (0.44–0.75) 0.56 (0.43–0.74)
* Younger adults (age 20–29 years); older adults (age 30 years).
HIV = human immunodeficiency virus; ART = antiretroviral therapy; HR = hazard ra-
tio; CI = confidence interval; WHO = World Health Organization; BMI = body mass 
index.
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DISCUSSION
This is the first study to examine ART retention in care and attri-
tion among younger vs. older adolescents and younger vs. older 
adults within the same cohort at a time when ART care was the 
same for both groups.19 Overall, there were no differences in ART 
retention within the adolescent group. Younger adults suffered 
more attrition from ART care compared to older adults; this was 
associated with late presentation for ART initiation, lower CD4 
counts and presentation at WHO clinical Stages III or IV. Across 
all age groups, LTFU was the main reason for attrition. Other find-
ings include higher proportions of young adolescents with Grade 
3 thinness compared to older adolescents. Among adults, being 
male and presenting later for ART care were more common 
among older vs. younger adults.
The strengths of the study included the large cohort of adult 
patients and standardised ART care within a well-resourced, 
NGO-supported clinic. Study data management quality was good, 
with validation at data collection and double-entry into EpiData. 
The study also adhered to the Strengthening the Reporting of OB-
servational studies in Epidemiology (STROBE) guidelines.22 Lim-
itations included a small cohort of adolescent patients, implying 
that these data must be interpreted with caution, and the use of 
routine clinic data, which may contain some inaccuracies.
In our clinic, where services were similar for adults and adoles-
cents, we did not demonstrate any differences in retention be-
tween younger vs. older adolescents up to 24 months of fol-
low-up. This lack of difference may be attributed to better ART 
care in an NGO-supported clinic with more than average re-
sources permitting efficient and timely management of all ART 
patients, whether adolescents or adults. Alternatively, the lack of 
difference could simply imply that adolescents within the 10–19 
year age group do not require differentiated care.
Our documentation of Grade 3 thinness among more younger 
adolescents on ART initiation may reflect residual stunting/wast-
ing associated with HIV infection in children.23 Infection with 
HIV may cause chronic diarrhoea in children, contributing to 
HIV-associated malnutrition. Other factors include late presenta-
tion for medical services and food insecurity in households with 
HIV-positive members, especially in limited-resource settings.24 
Policy guidelines should provide adequate nutritional care and 
support for younger adolescents in HIV care. More older adoles-
cents presented with normal BMI at initiation; this could be be-
cause, in this setting, older adolescents had their own income and 
were not relying on parental support.25
Among adults, there were more women in the younger age 
group. This can be attributed to fertility rates, which are highest 
in the 20–24 years age group,25 coupled with the well-established 
routine of HIV testing in ANC settings and subsequent ART initia-
tion among those who are HIV-infected.19,25
Older adults presented later in their disease, as reflected by 
lower CD4 counts, and were mostly men. These findings are in 
line with previous studies from Zimbabwe and elsewhere, where 
men tend to present late for HIV care.26–28
Attrition from HIV care was associated with late presentation, 
advanced HIV disease and low CD4 counts, similar to previous 
studies.8 We also found greater attrition amongst younger adults. 
This may be because younger adults are mobile and often migrate 
for work,29 or, as most of the young adults were females identified 
in ANC, they may have been lost to care in the postpartum pe-
riod, as shown in one South African study.30 Among adults, we 
found that initiation with d4T was associated with greater attri-
tion in comparison to TFV, probably because TFV has been shown 
to be safer and more effective than both d4T21 and ZDV.31 Both 
d4T and ZDV have been associated with greater mortality com-
pared to TFV.32 Zimbabwe has adapted recommendations to 
switch patients to a TFV-based regimen.19
After 24 months of follow-up, LTFU accounted for at least 70% 
of attrition across all age groups. The literature also shows that 
LTFU is the major cause of attrition in sub-Saharan Africa.6 There 
is a need to improve tracing of patients and document reasons 
why patients drop out of ART care.
This study has several implications. First, there is a need to 
focus more on younger adults to improve their retention in 
ART care. Our findings do not, however, support the need for 
differential care among adolescents, although further studies 
may be needed to validate this conclusion. Second, there is a 
clear need for innovative HIV-testing strategies that target 
men, especially younger men, for early identification and diag-
nosis and improved linkage to HIV treatment and care services. 
Third, there is a need to improve patient tracing procedures 
across all age groups to better retain patients in care. Fourth, 
the high proportion of malnourished younger adolescents 
highlights the importance of routinely assessing nutritional 
status, particularly in this age group, followed by provision of 
therapeutic feeding.
In conclusion, we found that younger adults demonstrated 
greater attrition from ART than older adults and may require 
more attention to improve retention. We were unable to find dif-
ferences in attrition among younger vs. older adolescents. A more 
focused approach is needed to improve retention in ART care 
amongst young adults. We also found that loss to follow-up was 
the main reason for attrition across all age groups; tracing proce-
dures should be improved in all patients.
TABLE 7 Attrition outcomes stratified by age group among HIV-infected patients enrolled on ART at Epworth 
Polyclinic, Epworth, Zimbabwe, 2010–2011
Attrition outcomes
Age group
Younger adolescents
(age 10–14 years)
n = 17
n (%)
Older adolescents
(age 15–19 years)
n = 18
n (%)
Younger adults
(age 20–29 years)
n = 94
n (%)
Older adults
age 30 years)
n = 345
n (%)
Defaulted 1 (6) 1 (6) 8 (9) 59 (12)
LTFU 14 (82) 14 (78) 74 (79) 339 (72)
Died 1 (6) 3 (17) 11 (12) 68 (14)
Stopped ART 1 (6) 0 (0) 1 (1) 8 (2)
HIV = human immunodeficiency virus; ART = antiretroviral therapy; LTFU = lost to follow-up.
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Contexte  :  Un centre de santé soutenu par une organisation non 
gouvernementale offrant des services de santé, notamment les 
services de traitement antirétroviral (TAR).
Objectif  :  Comparer la rétention du TAR entre des adolescents plus 
jeunes (10–14 ans) et plus âgés (15–19 ans) et des adultes plus jeunes 
(20–29 ans) et plus âgés (30 ans) et déterminer les facteurs associés 
à l’attrition et spécifiques des adolescents et des adultes parmi ceux 
qui ont mis en route du TAR en 2010–2011.
Schéma  :  Etude rétrospective de cohorte.
Résultats  :  L’étude a inclus 110 (7%) adolescents et 1484 (93%) 
adultes. Aucune différence en termes de rétention n’a été observée 
entre les adolescents plus jeunes et plus âgés à 6, 12 et 24 mois. 
Davantage des plus jeunes adolescents ont été initiés au traitement 
avec un index de masse corporelle 16 kg/m2 comparé aux 
adolescents plus âgés (64% contre 47% ; P = 0,04). Il y avait plus de 
femmes (74% contre 52% ; P  0,001) et moins de patients 
démarrant le TAR avec un comptage de CD4  350 cellules/mm3 
(77% contre 81% ; P = 0,007) parmi les adultes plus jeunes comparés 
aux plus âgés. Les adultes plus jeunes ont eu davantage d’attrition à 
tout moment que les plus âgés. Aucun facteur de risque d’attrition 
n’a été observé parmi les adolescents. Chez les adultes, les facteurs 
associés à l’attrition ont inclus l’âge plus jeune, un comptage de CD4 
plus faible et une infection au virus de l’immunodéficience humaine 
plus avancée lors de la mise en route du traitement et son initiation 
dans le cadre d’un protocole basé sur la stavudine.
Conclusion  :  Les adultes plus jeunes ont eu davantage d’attrition et 
devraient susciter davantage d’attention. Nous n’avons pas pu 
démontrer de différences d’attrition entre les adolescents plus jeunes 
et plus âgés. La perte de vue a été la cause principale d’attrition dans 
tous les groupes d’âge. Dans l’ensemble, un démarrage plus précoce 
du TAR parait important pour améliorer la rétention du TAR chez les 
adultes.
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Marco de referencia: Un consultorio administrado por una 
organización no gubernamental que presta servicios de salud, como 
la administración del tratamiento antirretrovírico (TAR).
Objetivo: Comparar la fidelización al TAR entre los jóvenes (de 10 a 
14 años) y los adolescentes mayores (de 15 a 19 años) y entre los 
adultos jóvenes (de 20 a 29 años) y los adultos de más edad (a partir 
de los 30 años) y determinar los factores específicos de los 
adolescentes y los adultos que se asocian con la tasa de abandono, 
en las personas que iniciaron el tratamiento del 2010 al 2011.
Método: Fue este un estudio de cohortes retrospectivo.
Resultados: Se incluyeron en el estudio 110 adolescentes (7%) y 
1484 adultos (93%). No se observaron diferencias en la fidelización 
de los jóvenes y los adolescentes mayores a los 6, 12 y 24 meses. En 
el grupo de adolescentes jóvenes, recibió TAR una proporción mayor 
de los que presentaban un índice de masa corporal 16 kg/m2 que 
en el grupo de adolescentes mayores (64% contra 47%; P = 0,04). En 
comparación con los adultos de más edad, los adultos jóvenes que 
iniciaron el tratamiento fueron con mayor frecuencia de sexo 
femenino (74% contra 52%; P  0,001), pero una proporción menor 
presentaba un recuento de linfocitos CD4  350 células/mm3 (77% 
contra 81%; P = 0,007). El abandono del tratamiento fue más 
frecuente en los adultos jóvenes que en los adultos mayores en todos 
los momentos examinados. No se observaron factores de riesgo de 
abandono en los adolescentes. En los adultos, los factores asociados 
con el abandono fueron una menor edad, el recuento más bajo de 
linfocitos CD4 y la enfermedad avanzada por el virus de la 
inmunodeficiencia humana en el momento de iniciar el tratamiento y 
el comienzo de un régimen basado en estavudina.
Conclusión: En los adultos más jóvenes la tasa de abandono del 
TAR fue más alta y precisan una mayor atención. No fue posible 
poner en evidencia diferencias en la tasa de abandono de los 
adolescentes más jóvenes y los adolescentes de mayor edad. La 
principal causa del abandono en todos los grupos de edad fue la 
pérdida durante el seguimiento. En general, la búsqueda temprana 
de TAR es un factor importante en la fidelización al tratamiento de 
los pacientes adultos.
